R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1904-1908

  Yong, Wei Peng ^a   Kim, Tae Won ^a   Undevia, Samir D ^a   Innocenti, Federico ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CYP2C9; Drug interaction; Pharmacokinetics; Warfarin; XK469

Indexed keywords

AMIODARONE; ATENOLOL; COMPLEMENTARY DNA; CYTOCHROME P450 2C9; DEXAMETHASONE; DEXTROPROPOXYPHENE; DIPHENOXYLATE; ENOXAPARIN; FENTANYL; FLUCONAZOLE; FUROSEMIDE; GABAPENTIN; GYRASE INHIBITOR; HYDROCODONE; HYDROMORPHONE; LANSOPRAZOLE; LEVOFLOXACIN; LORAZEPAM; METHYLPREDNISOLONE; ONDANSETRON; PARACETAMOL; PROPRANOLOL; RABEPRAZOLE; RAMIPRIL; SERTRALINE; TARTARIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; XK 469;

ARTICLE; COMPETITIVE INHIBITION; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INTERACTION; ENZYME INHIBITION; ENZYME KINETICS; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER MICROSOME; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTHROMBIN TIME;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; INTERNATIONAL NORMALIZED RATIO; MICROSOMES, LIVER; QUINOXALINES; REGRESSION ANALYSIS; WARFARIN;

EID: 67649336579     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.032     Document Type: Article

References (18)

1. Corbett T.H., LoRusso P., Demchick L., et al. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 16 2 (1998) 129-139
2. LoRusso P.M., Parchment R., Demchik L., et al. Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs 16 4 (1998) 287-296
3. Gao H., Huang K.C., Yamasaki E.F., et al. XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci USA 96 21 (1999) 12168-12173
4. Ding Z., Parchment R.E., LoRusso P.M., et al. The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clin Cancer Res 7 11 (2001) 3336-3342
5. Kessel D., and Horwitz J.P. Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor. Cancer Lett 168 2 (2001) 141-144
6. Lin H., Liu X.Y., Subramanian B., et al. Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer 97 1 (2002) 121-128
7. Lin H., Subramanian B., Nakeff A., and Chen B.D. XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway. Cancer Chemother Pharmacol 49 4 (2002) 281-286
8. Mensah-Osman E.J., Al-Katib A.M., and Mohammad R.M. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model. Clin Cancer Res 9 15 (2003) 5794-5797
9. Snapka R.M., Gao H., Grabowski D.R., et al. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280 4 (2001) 1155-1160
10. Anderson L.W., Collins J.M., Klecker R.W., et al. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol 56 4 (2005) 351-357
11. Bort R., Mace K., Boobis A., et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58 5 (1999) 787-796
12. Hamman M.A., Thompson G.A., and Hall S.D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54 1 (1997) 33-41
13. van Dijk K.N., Plat A.W., van Dijk A.A., et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 91 1 (2004) 95-101
14. Undevia S.D., Innocenti F., Ramirez J., et al. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer 44 12 (2008) 1684-1692
15. Purba H.S., Maggs J.L., Orme M.L., Back D.J., and Park B.K. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 23 4 (1987) 447-453
16. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 2 (2002) 229-243
17. Zheng H., Jiang C., Chiu M.H., Covey J.M., and Chan K.K. Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIbeta poison in the rat. Drug Metab Dispos 30 3 (2002) 344-348
18. Kunze K.L., Wienkers L.C., Thummel K.E., and Trager W.F. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24 4 (1996) 414-421